NCT06792825View on ClinicalTrials.gov

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

PHASE2RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

July 8, 2029

Study Completion Date

July 8, 2031

Conditions
Follicular LymphomaMarginal Zone Lymphoma
Interventions
DRUG

Tafasitamab

Tafasitamab 12 mg/kg IV on Day 1, Day 8, Day 15 and day 22.

DRUG

Rituximab

Rituximab 375 mg/m2 IV on day 1

DRUG

Lenalidomide

Lenalidomide 20 mg PO Day 1 through Day 21

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center, Minneapolis

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER